V

Voyager Therapeutics

VYGR

8.67000
USD
-0.59
(-6.37%)
مفتوح الان
حجم التداول
19,710
الربح لكل سهم
0
العائد الربحي
0
P/E
25
حجم السوق
363,191,472
أصول ذات صلة
A
ALNY
31.19
(13.13%)
268.66 USD
B
BLUE
-0.06000
(-5.26%)
1.08000 USD
C
CLLS
-0.11000
(-4.89%)
2.14000 USD
C
CRIS
-0.60000
(-11.05%)
4.83000 USD
C
CRSP
-2.450
(-4.28%)
54.840 USD
E
EDIT
-0.28500
(-5.26%)
5.13500 USD
N
NTLA
-1.100
(-4.19%)
25.130 USD
REGN
13.14
(1.22%)
1,091.19 USD
S
SGMO
-0.09690
(-12.11%)
0.70340 USD
VRTX
9.75
(1.97%)
505.40 USD
الأخبار المقالات

العنوان: Voyager Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.